What's in Dompé Farmaceutici S.p.A's pipeline?

Dompé Farmaceutici S.p.A has 12 drugs in our index: 3 marketed, 0 filed, 3 in Phase 3, 4 in Phase 2, 2 in Phase 1.

Which companies overlap with Dompé Farmaceutici S.p.A's portfolio?

Top competitors by shared drug class: Actavis Inc., Amneal Pharmaceuticals, LLC, Amzell, Assaf-Harofeh Medical Center, Azienda USL Reggio Emilia - IRCCS.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/domp-farmaceutici-s-p-a.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Dompé Farmaceutici S.p.A — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dompé Farmaceutici S.p.A pipeline: 3 marketed, 0 filed, 3 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 3 Phase 3 4 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Ketoprofen Lysine Salt	Ketoprofen Lysine Salt	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2	Pain Management / Rheumatology
OXERVATE® 0.002%	OXERVATE® 0.002%	marketed	Recombinant growth factor	Nerve growth factor receptor (TrkA, p75NTR)	Ophthalmology
Oxervate	Oxervate	marketed		High affinity nerve growth factor receptor, Tumor necrosis factor receptor superfamily member 16	Oncology
Libexin®	Libexin®	phase 3	Non-narcotic antitussive		Respiratory / Pulmonology
DFL24498	DFL24498	phase 3			Oncology
OKITASK®	OKITASK®	phase 3	Ophthalmic anti-inflammatory/corneal healing agent		Ophthalmology

Therapeutic area mix

Oncology · 2
Ophthalmology · 2
Other · 1
Pain Management / Rheumatology · 1
Respiratory / Pulmonology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Actavis Inc. · 1 shared drug class
Amneal Pharmaceuticals, LLC · 1 shared drug class
Amzell · 1 shared drug class
Assaf-Harofeh Medical Center · 1 shared drug class
Azienda USL Reggio Emilia - IRCCS · 1 shared drug class
Bausch & Lomb Incorporated · 1 shared drug class
Bayer · 1 shared drug class
Abbott · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Dompé Farmaceutici S.p.A:

Cite this brief

Drug Landscape (2026). Dompé Farmaceutici S.p.A — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/domp-farmaceutici-s-p-a. Accessed 2026-05-17.